# Immune Response and Lipid Metabolism Genes Associated with Acute Cerebral Circulatory Failure in Pre-Eclampsia in a Central Asian Population

## TL;DR

This study identifies genetic markers linked to pre-eclampsia and cerebral complications in Kazakh women, which could help in early detection and treatment.

## Contribution

The study reports novel associations between immune and lipid metabolism genes and pre-eclampsia in a Central Asian population.

## Key findings

- Genes TLR4, PLEKHA1, PLEKHG1, APOE, FTO, and LPL were found to be in genetic equilibrium in the Kazakh sample.
- Minor allele frequencies for these genes suggest potential roles in pre-eclampsia and cerebral complications.
- The findings may aid in developing personalized prevention and treatment strategies for pre-eclampsia.

## Abstract

The aim of this study was to determine the association of immune response and lipid metabolism genes with the development of pre-eclampsia and related acute cerebral circulatory disorders in Kazakh women.

Minor allele frequencies of immune response and lipid metabolism genes were determined in 1,800 healthy participants stored in the Miras Biobank of the Scientific Centre of Obstetrics, Gynaecology, and Perinatology Joint Stock Company.

The main results of the study showed that TLR4 (rs4986790), PLEKHA1 (rs2281673), PLEKHG1 (rs9478812), APOE (rs7412), FTO (rs1421085) and LPL (rs285) genes were in genetic equilibrium (p > 0.05), indicating that the sample was representative and there were no significant evolutionary pressures on the studied genes. The frequencies of minor alleles in the studied sample of Kazakhs were: TLR4 – 3.3%, PLEKHA1 – 5.9%, PLEKHG1 – 27.0%, APOE – 7.8%, FTO – 28.3% and LPL – 36.0%.

The obtained data can be used for further genetic studies, as well as for the development of individualised strategies for the prevention and treatment of pre-eclampsia and related complications. The identified genetic markers may help in early detection of women at increased risk of developing these conditions, which will contribute to improving clinical outcomes and reducing maternal and perinatal mortality.